Characteristic | N (%) | Global disability | Residual physical disability | Residual mental disability | ||
---|---|---|---|---|---|---|
Bifactor | Unidimensional | Unidimensional | Bifactor | Bifactor | ||
Patterna(95% CI) | Patterna(95% CI) | Summedb(95% CI) | Patterna(95% CI) | Patterna(95% CI) | ||
Age at assessment (y.) | ||||||
≤ 35 | 749 (19.1) | 45.2 (44.1, 46.2)*** | 44.6 (43.6, 45.7)*** | 44.5 (43.5, 45.6)*** | 42.5 (41.7, 43.4)*** | 41.2 (40.2, 42.2)*** |
36 – 55 | 1760 (44.8) | 50.3 (49.6, 51.0) | 50.1 (49.4, 50.8) | 50.0. (49.3, 50.7) | 47.8 (47.1, 48.4) | 47.4 (46.6, 48.2) |
≥ 56 | 1417 (36.1) | 52.2 (51.5, 53.0) | 52.7 (52.0, 53.5) | 52.9 (52.2, 53.7) | 56.7 (55.9, 57.5) | 57.9. (57.0, 58.8) |
Disease duration (y.) | ||||||
≤ 10 | 1713 (43.6) | 46.2 (45.5, 46.9)*** | 45.7 (45.0, 46.5)*** | 45.5 (44.8, 46.2)*** | 45.2 (44.5, 45.8)*** | 44.3 (43.6, 45.0)*** |
11 – 20 | 1109 (28.3) | 51.7 (50.9, 52.6) | 51.8 (51.0, 52.7) | 51.9 (51.1, 52.7) | 50.6 (49.7, 51.5) | 50.7 (49.7, 51.7) |
≥ 21 | 1104 (28.1) | 54.2 (53.3, 55.0) | 54.8 (54.0, 55.6) | 55.1 (54.3, 55.9) | 56.9 (56.0, 57.8) | 58.2 (57.1, 59.2) |
Gender | ||||||
Female | 3102 (79.4) | 49.7 (49.2, 50.2)** | 49.6 (49.1, 50.1)*** | 49.5 (49.0, 50.0)*** | 48.8 (48.3, 49.3)*** | 48.5. (47.9, 49.1)*** |
Male | 803 (20.6) | 51.3 (50.2 52.4) | 51.6 (50.5, 52.7) | 51.9 (50.8, 53.0) | 54.8 (53.7, 55.9) | 55.6 (54.4, 56.9) |
Race/Ethnicity | ||||||
White | 3491 (90.2) | 49.8 (49.3, 50.3)*** | 49.8 (49.3, 50.3)*** | 49.7 (49.3, 50.2)*** | 50.0 (49.5, 50.5)* | 50.0 (49.4, 50.6)* |
African American | 132 (3.4) | 50.7 (48.2, 53,2) | 51.0 (48.6, 53.4) | 51.5 (49.0, 54.0) | 51.8 (49.0, 54.5) | 52.1 (48.9, 55.3) |
Hispanic/Latino | 120 (3.1) | 48.1. (45.2, 51.0) | 47.9 (45.0, 50.8) | 47.8 (44.8, 50.5) | 46.5 (43.8, 49.2) | 45.9. (42.7, 49.1) |
Native American | 76 (2.0) | 56.7 (53.3, 60.1) | 56.6 (53.2, 59.9) | 56.7 (53.3, 60.1) | 48.3 (45.6, 51.1) | 48.0 (44.8, 51.3) |
Other | 49 (1.3) | 53.4 (48.5, 58.1) | 53.1 (48.3, 57.9) | 53.3 (48.4, 58.3) | 47.3. (43.6, 51.0) | 46.8. (42.4, 51.2) |
Disease modifying therapy | ||||||
Yes | 2614 (66.6) | 49.2. (48.6, 49.8)*** | 49.2 (48.6, 49.7)*** | 49.1 (48.5, 49.7)*** | 48.8. (48.2, 49.3)*** | 48.6 (47.0, 49.2)*** |
No | 1312 (33.4) | 51.6 (50.8, 52.4) | 51.7 (50.8, 52.5) | 51.8 (51.0, 52.7) | 52.4 (51.5, 53.3) | 55.6 (54.4, 56.9) |
Year of assessment | ||||||
2003-2005 | 1640 (41.8) | 50.0 (49.2, 50.7)** | 50.3 (49.5, 51.0)* | 50.6 (49.8, 51.3)* | 51.1 (50.4, 51.9)*** | 51.3 (50.4, 52.2)*** |
2006-2008 | 957 (24.4) | 48.9 (47.9, 49.8) | 49.0 (48.0, 49.9) | 49.0 (48.1, 50.0) | 49.1 (48.1, 50.0) | 48.9 (47.7, 50.0) |
2009-2011 | 1329 (33.8) | 50.8 (50.0, 51.6) | 50.4 (49.6, 51.2) | 50.0 (49.2, 50.8) | 49.3 (48.5, 50.1) | 49.2 (48.3, 50.1) |